Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.
Cleveland Clinic researchers have used nanoparticles to develop a potential vaccine candidate against Dabie Bandavirus, formerly known as Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV), a tick-borne virus that currently has no prevention, treatment or cure.
The bivalent COVID-19 vaccine developed by GSK and Sanofi shows promising results with a 64.7% overall effectiveness against symptomatic COVID-19, according to a phase 3 trial. The vaccine performs especially well as a booster, achieving 75.9% efficacy in non-naïve subjects.
An article published in NPJ Aging, a Springer Nature journal, reveals that natural production of auto-antibodies increases with age and that infection by SARS-CoV-2 can exacerbate production of auto-antibodies relating to auto-immune diseases, helping to explain why aging increases the chances of developing severe COVID-19.
A blog post shared on Facebook claimed that covid-19 vaccines have killed some 676,000 Americans.
Various medical circumstances, including heart attacks and extreme cases of COVID-19, necessitate the use of anticoagulants, medicines that prevent blood clots
COVID-19 can increase the risk of various autoimmune diseases; however, this risk appears to be mitigated by vaccination against COVID-19.
Platelets, or thrombocytes, are specialized cellular fragments that form blood clots when we get scrapes and traumatic injuries. Viral infections, autoimmune disease, and other conditions can cause platelet levels to drop throughout the body, termed thrombocytopenia.
Researchers evaluate the risks of possible adverse events following COVID-19 mRNA vaccination in the elderly.
Researchers explore the potential association of both arterial and venous thrombosis with COVID-19 vaccination.
Detection and response to a dengue outbreak in Florida during the COVID-19 pandemic in 2020, highlighting the challenges of diagnosing febrile illnesses and the need for surveillance. This study examines the impact and management of dengue cases in the context of the ongoing pandemic.
The study reveals that MIS-C patients, post SARS-CoV-2 infection, develop a unique immune response against the virus' N protein, indicating a cross-reactivity with the self-protein SNX8, which might link the infection to the ensuing inflammatory syndrome.
Researchers described severe and fatal infections in neonates caused by a new echovirus 11 (E-11) variant in France.
HealthPartners Institute researchers have published new data in JAMA Network Open that shows monovalent COVID-19 booster vaccinations administered in early pregnancy (before 20 weeks' gestation) were not associated with miscarriage.
A new way to identify more specific, higher-risk groups of older surgical patients can help in clinical decision-making and accurately comparing the performance of one hospital to another, according to research published in the Journal of the American College of Surgeons.
Announcing a new article publication for Cardiovascular Innovations and Applications journal. Spontaneous heparin-induced thrombocytopenia is a pro-thrombotic syndrome in which anti-heparin antibodies develop without heparin exposure.
Researchers examined the factors associated with stroke following coronavirus disease 2019 (COVID-19) vaccination.
Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" phenotype.
Researchers determined the association between adverse events of special interest (AESIs) following BNT162b2 vaccination, a coronavirus disease 2019 (COVID-19) vaccine based on the messenger ribonucleic acid (mRNA) technology.
Researchers evaluated adverse events in older adults after mRNA vaccination for COVID-19.
A recent Eurosurveillance study focused on estimating the incidence of a prespecified list of adverse events following the first and second doses of the COVID-19 vaccination.